Over the past two decades, monoclonal antibodies (mAbs) have played a pivotal role in cancer treatment; however, their efficacy as anticancer agents is constrained by tumor heterogeneity and the ...

Geoffrey Shouse, DO, PhD, discusses what motivated this retrospective review of bispecific antibodies in diffuse large B-cell lymphoma at City of Hope.

Having picked up a pipeline of oncology drugs as part of a merger last year, NAYA Biosciences is reverting back to its ...

Merus leads biotech with its innovative antibody platforms, strong financials, and promising petosemtamab targeting cancer.

Bispecific antibodies first reached patients as cancer treatments, but a growing number of companies are working to expand these therapies to autoimmune diseases. Sanofi is adding a new contender ...

Building on this foundation, bispecific and trispecific antibodies have emerged as innovative biologics aimed at simultaneously engaging multiple targets, promising improved efficacy and safety ...

and how partnerships among academic centers, manufacturers, and community practices can help accelerate the adoption of bispecific antibodies.

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities EP: 15 . Future Breakthroughs: What’s Next for Bispecific Antibodies in Oncology?

DR-0201 is a potential first-in-class CD20-directed bispecific antibody that targets and engages specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion via targeted ...